Mounjaro vs Zepbound

Summary: Mounjaro and Zepbound are the exact same drug, tirzepatide, sold under two brand names so Eli Lilly can run separate FDA indications and let insurers split coverage between type 2 diabetes and chronic weight management.

This content is for informational purposes only and is not medical advice. Always consult a qualified healthcare provider before starting, changing, or stopping any medication.

Mounjaro and Zepbound are the same drug. Both contain tirzepatide, both are made by Eli Lilly, both are once-weekly subcutaneous injections, both ladder up through the same 2.5, 5, 7.5, 10, 12.5, and 15 mg doses, and both come in identical single-use auto-injector pens ^[1][2]. The only meaningful differences are the label on the box, the FDA indication printed on that label, and the insurance and pricing pathways that follow from that indication.

If a clinician hands you a Mounjaro pen and a Zepbound pen at the same dose, the medication inside is pharmacologically identical. The molecules are the same. The fill volume is the same. The blood levels and clinical effect are the same.

Why one molecule has two brand names

Tirzepatide was approved by the FDA in May 2022 as Mounjaro for the treatment of type 2 diabetes ^[1]. Eighteen months later, in November 2023, the same molecule was approved again under a new brand, Zepbound, for chronic weight management in adults with obesity (BMI 30 or higher) or overweight (BMI 27 or higher) with a weight-related comorbidity ^[2][3]. A third indication was added to Zepbound in December 2024 for moderate to severe obstructive sleep apnea in adults with obesity, based on the SURMOUNT-OSA trial ^[5].

Why not just expand Mounjaro's label to include weight loss? Two reasons, both about money.

The first is regulatory. Each FDA-approved indication requires its own new drug application file, its own pivotal trials, its own prescribing information, and its own boxed warnings. Lilly ran the SURPASS trials for type 2 diabetes and the SURMOUNT trials for obesity. Submitting these as separate applications under separate brand names let the company stage the launches, time the marketing, and keep the labeling clean for each population.

The second is insurance. US payers categorize coverage by indication. Most commercial insurance plans cover type 2 diabetes drugs as a standard medical benefit. Many of those same plans exclude anti-obesity medications entirely, treat them as a separate pharmacy carve-out, or require step therapy and prior authorization that diabetes drugs do not face. By selling tirzepatide as Mounjaro for diabetes and Zepbound for weight loss, Lilly lets payers approve one without being forced to approve the other. An employer that wants to cover diabetes treatment but exclude weight loss drugs can do exactly that.

Side-by-side comparison

Identical clinical effect, different label populations

The clinical evidence behind each brand was generated in different populations, but the molecule is the same and the effects carry across.

For type 2 diabetes, the SURPASS program showed Mounjaro lowering A1C by 1.9 to 2.6 percentage points at the higher doses, with weight loss of 12 to 25 pounds depending on dose and trial. For weight management, the SURMOUNT-1 trial randomized 2,539 adults with obesity (without diabetes) to placebo or tirzepatide 5, 10, or 15 mg weekly for 72 weeks ^[4]. Mean weight loss was 15.0% at 5 mg, 19.5% at 10 mg, and 20.9% at 15 mg, versus 3.1% on placebo. SURMOUNT-OSA then showed that the same molecule reduced obstructive sleep apnea events per hour by about 25 to 29 in adults with obesity-related OSA, leading to Zepbound's second indication ^[5].

These trials used the same molecule at the same doses. The reason they read out differently is that they enrolled different patient populations and measured different primary endpoints. There is no separate "Zepbound formulation" or "Mounjaro formulation" doing the work. It is one drug.

Side effects are the same

Both labels list the same adverse event profile because the underlying molecule is the same ^[1][2]. The most common side effects in trials were:

• Nausea (in the 25 to 33% range across doses)
• Diarrhea (around 15 to 23%)
• Decreased appetite
• Vomiting
• Constipation
• Indigestion and abdominal pain
• Injection site reactions

Both carry the same boxed warning for thyroid C-cell tumors based on rodent studies, and both are contraindicated in patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. Both list acute pancreatitis, gallbladder disease, acute kidney injury (typically from dehydration secondary to GI side effects), hypoglycemia when combined with insulin or sulfonylureas, hypersensitivity reactions, severe gastrointestinal disease, diabetic retinopathy complications in people with diabetes, and acute cholecystitis as warnings or precautions.

If you tolerate one, you tolerate the other. If you have side effects on one, switching to the other at the same dose does nothing, because there is nothing to switch to.

Price and the LillyDirect Self Pay difference

The cash list prices are nearly identical. As of 2026, Mounjaro carries a list price around $1,069 per month and Zepbound around $1,059 per month for the auto-injector pens, regardless of dose. With commercial insurance and the manufacturer savings card, eligible patients can pay as little as $25 per month for either drug if their plan covers it, or several hundred dollars per month if their plan does not cover the indication but the savings card still applies.

The biggest pricing asymmetry between the two brands is LillyDirect Self Pay, the manufacturer's cash-pay portal that sells single-dose vials of tirzepatide directly to consumers without going through insurance. LillyDirect ships Zepbound vials only, at the 2.5 mg and 5 mg strengths. As of 2026, those vials are priced at roughly $349 for the 2.5 mg dose and $499 for the 5 mg dose per month's supply, both substantially below the auto-injector list price.

This vial-only-for-Zepbound design is another consequence of the brand split. Lilly built the cash-pay vial channel specifically for the weight management population because that population is more likely to be paying out of pocket. Diabetes patients are far more likely to have their Mounjaro covered through standard insurance, so a parallel cash channel for Mounjaro was not built.

Insurance: same molecule, two different prior authorization processes

This is where the brand split has the biggest real-world consequence. Insurance plans evaluate Mounjaro and Zepbound as separate drugs.

A typical commercial insurance scenario in 2026:

• Type 2 diabetes diagnosis, Mounjaro request. Usually covered with standard prior authorization showing A1C above 7%, prior trial of metformin, and documentation of the diabetes diagnosis. Tier 2 or Tier 3 formulary placement is common.
• Obesity diagnosis without diabetes, Zepbound request. Coverage varies wildly. Some plans cover it on the same tier as other anti-obesity medications with BMI documentation, weight history, and prior diet and exercise attempts. Many plans exclude anti-obesity medications categorically. Some employers self-fund their plans and explicitly carve out GLP-1s for weight loss.
• Obesity diagnosis, Mounjaro request "for weight loss." Almost always denied. Prior authorization requirements specifically tie Mounjaro coverage to a type 2 diabetes diagnosis. Off-label requests get rejected on the first round and typically lose on appeal because Zepbound exists for this exact indication.
• Type 2 diabetes plus obesity, either request. Mounjaro is usually the easier approval because the diabetes pathway is older and more standardized. A clinician who wants to leverage the weight loss data can prescribe Mounjaro on the diabetes indication and capture the weight benefit as a side effect of the same molecule.

The cleanest summary: the brand you should ask for is the one that matches your diagnosis. If you have type 2 diabetes, ask for Mounjaro. If you have obesity without diabetes, ask for Zepbound. Asking for the "wrong" brand for your diagnosis is the most common reason coverage requests get denied for tirzepatide.

Switching between Mounjaro and Zepbound

Because the molecule, dose, and pen design are identical, switching between brands is pharmacologically trivial. You move from 5 mg Mounjaro to 5 mg Zepbound and your body does not notice. Clinicians switch patients across the brands routinely when insurance coverage changes, when a diagnosis is updated, or when one brand is in shortage and the other is not.

Practical points when switching:

• Continue the same dose. Do not restart the titration ladder. If you were stable on 10 mg Mounjaro, you switch to 10 mg Zepbound at your next weekly dose.
• Continue the same weekly schedule. If you injected Sunday morning on Mounjaro, you inject Sunday morning on Zepbound.
• Storage and handling are identical (refrigerated, can sit at room temperature for limited periods per label).
• Your savings card and copay assistance need to be re-enrolled. The Mounjaro savings card does not work for Zepbound prescriptions and vice versa, because the NDC numbers are different.

The opposite move (switching off tirzepatide entirely to a different molecule like semaglutide) is a real switch and requires re-titration. Moving between Mounjaro and Zepbound is a paperwork change, not a clinical one.

Which one should you ask your doctor for?

The decision tree is short.

• Diagnosed with type 2 diabetes: Mounjaro. Insurance is more likely to cover it, the prior authorization is more standardized, and the savings card economics are usually better.
• Diagnosed with obesity or overweight with comorbidity, no diabetes: Zepbound. It is the only one approved for this indication. Off-label Mounjaro requests will be denied. If you cannot get coverage, the LillyDirect Self Pay vial program for the 2.5 mg and 5 mg starting doses is the cheapest legitimate cash path.
• Both diabetes and obesity: Either can work clinically. Mounjaro is usually the easier approval. Some clinicians prefer to document the obesity-specific outcome data and prescribe Zepbound, especially in patients whose primary goal is weight management and whose A1C is well-controlled on metformin alone.
• Diagnosed with obstructive sleep apnea and obesity: Zepbound is the only one with the OSA label ^[5]. Mounjaro is not approved for OSA.

Mounjaro vs Zepbound FAQ

Are Mounjaro and Zepbound the same drug?

Yes. Both contain tirzepatide, both are made by Eli Lilly, both are dosed identically at 2.5 to 15 mg weekly, and both use the same single-use auto-injector pen. The only differences are the brand name, the FDA indication, and the insurance pathway.

Why does Eli Lilly sell tirzepatide as two different brands?

Separate brands let Lilly hold separate FDA indications (type 2 diabetes for Mounjaro, weight management and OSA for Zepbound) and let insurers approve or deny coverage by indication without affecting the other.

Is Zepbound vs Mounjaro for weight loss a real comparison?

No. They are the same molecule at the same dose, so weight loss results are identical when matched. The SURMOUNT-1 trial showed up to 20.9% mean weight loss at 15 mg over 72 weeks, and that result applies to tirzepatide regardless of which brand name is on the box.

Are Zepbound vs Mounjaro side effects different?

No. Both labels list the same adverse events because the active ingredient is the same. Nausea, diarrhea, vomiting, constipation, and decreased appetite are the most common, with the same dose-response pattern and the same boxed warning for thyroid C-cell tumors.

Is tirzepatide vs Mounjaro the same drug?

Tirzepatide is the generic name. Mounjaro is the brand name Eli Lilly sells tirzepatide under for type 2 diabetes. There is no clinical difference between tirzepatide and Mounjaro at the same dose, only label and packaging.

Can I switch from Mounjaro to Zepbound at the same dose?

Yes, with no titration needed. If you were stable on 7.5 mg Mounjaro, you switch to 7.5 mg Zepbound at your next weekly dose. The molecule is identical, so clinical effect carries over.

Which is cheaper, Mounjaro or Zepbound?

Brand pen list prices are nearly identical at around $1,059 to $1,069 per month. Zepbound is cheaper if you use the LillyDirect Self Pay vials (2.5 mg or 5 mg only), which run roughly $349 to $499 per month. Mounjaro does not have a vial cash-pay program.

Will my insurance cover Mounjaro for weight loss?

Almost never. Mounjaro's prior authorization criteria require a type 2 diabetes diagnosis. Off-label use for weight loss is consistently denied because Zepbound exists for that indication. If weight loss is the goal, ask your doctor for Zepbound.

Will my insurance cover Zepbound?

It depends on the plan. Many commercial plans cover anti-obesity medications with BMI and prior weight loss attempt documentation. Many others exclude the entire drug class. Check your formulary or call the number on your card before assuming coverage.

Is there a generic tirzepatide?

No. Tirzepatide is under patent protection in the US through the early 2030s. The only legal sources of tirzepatide in the US are Mounjaro, Zepbound, and FDA-registered compounding pharmacies operating within current regulatory rules.